Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group

2023
Written By Guest User
Guest User
Previous

Ironwood Enters into Definitive Agreement to Acquire VectivBio
Next

Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study